ID: MRFR/HC/6835-CR | September 2019 | Region: Global | 133 pages
Global Glioblastoma Market is expected to register a CAGR of 7.40% to reach 1,643.4 million by 2025. Glioblastoma is a type of brain tumor. The increasing occurrences of glioblastoma, a type of brain tumor, coupled with extensive research in glioblastoma treatment, and the rising adoption of chemotherapy are expected to fuel the growth of the global glioblastoma market. However, the high cost of drugs and the failure of drug candidates in clinical trial phases are anticipated to hamper the market growth.
The increasing incidence rate of glioblastoma is expected to fuel the growth of the global glioblastoma market. According to the statistics published in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastoma has an incidence rate of 3.19 per 100,000 persons in the US. The growing prevalence indirectly increases the healthcare expenditure of the people as well as the government. This motivates the players operating in the market to come up with alternatives for the treatment of glioblastoma. Thus, this is likely to fuel the growth of the global glioblastoma market during the forecast period.
Global Glioblastoma Market Share, by End User, 2018 (%)
Source: MRFR Analysis
The global glioblastoma market has been segmented by type, treatment, and end user. The market, based on type, has been bifurcated into primary glioblastoma and secondary glioblastoma. Based on treatment, the glioblastoma market has been segregated into surgical procedure, radiation therapy, chemotherapy, and others. The global glioblastoma market, based on end user, has been divided into hospitals, specialty clinics and centers, and others. The specialty clinics and centers held a share of 36.8% in 2018.
Western Europe Glioblastoma Market Share, 2018 (%)
Source: MRFR Analysis
The global glioblastoma market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to dominate the global glioblastoma market. The growth in this region can be attributed to the increased cases of glioblastoma and brain tumors. Moreover, the approval of drugs helps in maximizing the growth of the market in this region.
Europe held a substantial share in the global glioblastoma market. This can be attributed to a large number of clinical trials in the region. For instance, Merck KGaA along with Vaximm GmbH is involved in Phase I and II trials to evaluate the efficacy and safety of VXM01 in combination with Avelumab in patients with resectable and non-resectable progressive glioblastoma following tumor resection and radio-chemotherapy containing temozolomide.
Asia-Pacific is estimated to be the fastest-growing region in the global market. The rise in the improved healthcare infrastructure promises a high level of research on the treatment of glioblastoma in the region.
The glioblastoma market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth in this region. Rising awareness regarding health and availability of new treatment methods are expected to drive the market growth during the assessment period.
The prominent players in the global glioblastoma market are F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel).
Some of the key strategies followed by players operating in the global glioblastoma market were innovation, product development, and acquisition & mergers.
Global Glioblastoma Market, by Type
Global Glioblastoma Market, by Treatment
Global Glioblastoma Market, by End User
Global Glioblastoma Market, by Region
Available Additional Customizations
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||By Type, By Treatment , By End User and By Region|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel)|
|Key Market Opportunities||
|Key Market Drivers||The increasing occurrences of glioblastoma, a type of brain tumor, coupled with extensive research in glioblastoma treatment.|
Frequently Asked Questions (FAQ) :
glioblastoma market is expected to reach a valuation of USD 1.6 billion by 2025.
The global market is expected to exhibit a strong 7.4% CAGR over the forecast period from 2019 to 2025.
The growing prevalence of glioblastoma is the major driver for the global market.
The Americas are likely to dominate the global glioblastoma market.
Leading players in the market include F. Hoffman-La Roche, Merck, and Amgen, among others.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.